Risk Stratification & Monitoring: Tracking Your Progress
At a Glance
Doctors monitor pulmonary arterial hypertension (PAH) using a 4-strata risk model assessed every 3 to 4 months. By checking your symptoms, 6-minute walk distance, and NT-proBNP blood levels, your care team aims to keep you in the "low risk" zone and adjust treatments quickly if needed.
Monitoring Pulmonary Arterial Hypertension (PAH) is not just about checking your blood pressure; it’s a sophisticated process of “risk stratification.” By looking at several markers together, your care team determines if your current treatment is working or if you need to “turn up the volume” on your therapy.
The 4-Strata Risk Model: Your “Green Light” Goal
The most current medical guidelines (2022 ESC/ERS) use a 4-strata risk model to track your progress [1]. This model is more precise than older versions because it splits the “middle” group into two, allowing doctors to catch small changes in your health earlier [2].
Your risk is categorized into four “zones”:
- Low Risk (Green Light): Your disease is stable, and your 1-year survival probability is very high (over 97%) [2][3].
- Intermediate-Low Risk: You are doing well, but there is room for improvement to get you to “Low Risk.”
- Intermediate-High Risk: This is a warning sign that your current treatment may not be enough [2].
- High Risk (Red Light): Your heart is under significant stress, and immediate, intensive treatment changes are usually required [1].
The Three Main Markers
To place you in a risk zone, your doctor looks at three primary pieces of information [2][3]:
- WHO Functional Class (FC): This is a simple 1-to-4 scale of how you feel. Class I or II means you have little to no trouble with daily activities (Low Risk). Class III or IV means you struggle even with light tasks or have symptoms at rest (High Risk).
- 6-Minute Walk Distance (6MWD): This measures your exercise capacity. Generally, walking more than 440 meters (about 1,440 feet) is considered low-risk [2].
- NT-proBNP (or BNP): This is a blood test that measures a hormone released when your heart is stretched or stressed. For the 4-strata model, an NT-proBNP level below 300 ng/L is a strong indicator of low risk [3].
Your Monitoring Schedule
Because PAH can change, frequent check-ups are the new standard. Current guidelines recommend a full risk assessment every 3 to 4 months [4]. If you are not in the “low-risk” zone, your doctor will likely recommend adding a new medication or adjusting your doses immediately, rather than waiting until your next visit [1][4].
Coping with “Scanxiety”
It is completely normal to feel a sense of dread or anxiety in the days leading up to your tests—a phenomenon often called scanxiety [5]. This stress peaks while waiting for results and can impact your quality of life [6][7].
- Knowledge is Power: Many patients find that “knowing their numbers” and understanding what the tests mean helps turn fear into a sense of control [8].
- Communication: Don’t hesitate to ask your team for your results as soon as they are available. Proactive education on what to expect during a test can also lower your stress levels [9].
Living with PAH: Daily Lifestyle Considerations
Beyond medical treatments, daily lifestyle choices play a massive role in living well with PAH:
- Low-Sodium Diet: Limiting salt is critical because sodium causes your body to retain fluid, putting extra strain on your already hard-working right heart.
- Safe Exercise: While intense or heavy weight-lifting should be avoided, supervised cardiopulmonary rehabilitation (light, monitored aerobic exercise) is highly recommended and can improve your strength and 6-minute walk distance.
- Air Travel and Altitude: High altitudes reduce the amount of oxygen in the air, which can cause your pulmonary arteries to constrict further. You may need supplemental oxygen to fly safely on an airplane or travel to higher elevation destinations. Always consult your doctor before booking a trip.
Other Tools: REVEAL Scores
In addition to the 4-strata model, your doctor might use the REVEAL 2.0 or REVEAL Lite 2.0 score. These are points-based systems that include other factors like your age, kidney function, and blood pressure to give a comprehensive view of your heart health [10][11].
Common questions in this guide
What is the 4-strata risk model for PAH?
What tests are used to monitor pulmonary arterial hypertension?
What is a good NT-proBNP level for a PAH patient?
How often should my doctor check my PAH risk score?
Can I travel on an airplane if I have PAH?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What was my risk score today using the 4-strata model? Am I in the 'low' or 'intermediate-low' group?
- 2.How did my 6-minute walk distance and NT-proBNP level compare to my last visit? Are they moving in the right direction?
- 3.If I'm not yet in the 'low-risk' category, what specific changes to my treatment do we need to make to get me there?
- 4.Is it normal for me to feel anxious before these tests, and does your clinic have resources to help me manage 'scanxiety'?
- 5.When is my next 3-to-4-month follow-up, and which tests will be performed then?
- 6.What are my specific lifestyle restrictions regarding exercise, salt intake, and travel (such as needing oxygen on a plane)?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (11)
- 1
Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension.
Lange TJ
Herz 2023; (48(4)):259-265 doi:10.1007/s00059-023-05179-1.
PMID: 37085727 - 2
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
Hoeper MM, Pausch C, Olsson KM, et al.
The European respiratory journal 2022; (60(1)) doi:10.1183/13993003.02311-2021.
PMID: 34737226 - 3
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.
Boucly A, Weatherald J, Savale L, et al.
The European respiratory journal 2022; (59(6)) doi:10.1183/13993003.02419-2021.
PMID: 34737227 - 4
Emerging therapies and new directions in the treatment of pulmonary arterial hypertension.
Kopeć G, Skride A, Ereminiene E, et al.
Kardiologia polska 2025; (83(1)):18-26 doi:10.33963/v.phj.104053.
PMID: 39743894 - 5
Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.
Dunsmore VJ, Neupert SD
Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.
PMID: 36964680 - 6
Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.
Khatri R, Quinn PL, Wells-Di Gregorio S, et al.
Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.
PMID: 39343818 - 7
Scanxiety Conversations on Twitter: Observational Study.
Bui KT, Li Z, Dhillon HM, et al.
JMIR cancer 2023; (9()):e43609 doi:10.2196/43609.
PMID: 37074770 - 8
Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases.
Schoenmaekers JJAO, Bruinsma J, Wolfs C, et al.
JTO clinical and research reports 2022; (3(10)):100401 doi:10.1016/j.jtocrr.2022.100401.
PMID: 36188631 - 9
Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.
King AL, Acquaye-Mallory AA, Vera E, et al.
BMC cancer 2023; (23(1)):262 doi:10.1186/s12885-023-10671-2.
PMID: 36944930 - 10
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
Benza RL, Kanwar MK, Raina A, et al.
Chest 2021; (159(1)):337-346 doi:10.1016/j.chest.2020.08.2069.
PMID: 32882243 - 11
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study.
Benza RL, Simonneau G, Ghofrani HA, et al.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2024; (43(10)):1756-1760 doi:10.1016/j.healun.2024.06.002.
PMID: 38852934
This page provides educational information about PAH risk stratification and monitoring guidelines. It does not replace professional medical advice, and you should always consult your cardiologist or pulmonologist regarding your specific test results and treatment plan.
Get notified when new evidence is published on Idiopathic/heritable pulmonary arterial hypertension.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.